International Pharmaceutical Students' Federation

Printer-friendly version
144th session of the Executive Board<br>24 January - 1 February 2019
Agenda Item: 
6.2 Member State mechanism on substandard and falsified medical products

Substandard and falsified medicines are two different threats to patient’s health that can result in death, disability, and increased illness for patients. However, their implications in healthcare go far beyond. From contributing to antimicrobial resistance to creating mistrust in healthcare systems and professionals, they contribute to added costs and further strain resources that are oftentimes already too thin. A coordinated response to this threat must tackle both substandard and of falsified medicines, acknowledging their differences and need for different approaches.

Robust regulatory oversight is key in combating substandard and falsified medicines. We urge Member States to put in place regulatory frameworks that effectively prevent these medicines from reaching and harming patients, including regulation on online sales of medical products.

Concurrent to this is the need for capacity building through embedding courses about substandard and falsified medical products in pharmacy school curriculum, especially in the context of the current environment of the manufacture and distribution of medical products as it evolves with new technologies. We believe that training pharmacists on the dangers of these products is paramount, as well as giving them the right tools to act upon it and report suspicious products. We stand ready to collaborate with WHO and its Member State Mechanism on this topic.

As partners in promoting global health, IPSF and members of Fight the Fakes are playing our roles in raising awareness on the dangers of substandard and falsified medicines and empowering people to act on this issue. We welcome the possibility of further collaboration with WHO to drive forward the endeavors of its Member State Mechanism, as we believe that a holistic approach encompassing collaboration between all stakeholders involved in the manufacture and distribution of medicines is essential in our fight against substandard and falsified medicines.